嗜铬细胞瘤切除术前省略α肾上腺素能阻滞剂剂量递增方案的实施
这项单中心前瞻性方案实施研究纳入82例嗜铬细胞瘤肾上腺切除术患者,比较省略术前α阻滞剂剂量递增(de-escalation)方案与既往剂量递增方案。结果显示de-escalation组术后去甲肾上腺素持续给药时间更短、住院时间更短,但术后症状性低血压发生率更高;术中高血压主要指标无显著差异,并发症率无显著差异。
要点
- 省略术前α阻滞剂剂量递增方案未增加术中高血压,但术后症状性低血压更常见。
- de-escalation方案术后去甲肾上腺素支持时间及住院时间显著缩短。
- 两组并发症率无显著差异,提示该方案在选定患者中可行。
核心结论
- 采用省略术前α阻滞剂剂量递增方案行嗜铬细胞瘤肾上腺切除术是安全的,并可缩短住院时间。
研究设计与样本
- 单中心方案实施评估,纳入2015至2023年因嗜铬细胞瘤行肾上腺切除术的患者,共82例,其中de-escalation组44例、剂量递增组38例。
- 术中血流动力学控制通过使用血管活性药物主动调整血压来调节。
主要发现
- 主要结局术中收缩压时间加权平均值高于200 mm Hg的中位数在de-escalation组为0.01 [0.0-0.4] mm Hg,剂量递增组为0.0 [0.0-0.1] mm Hg(P=0.073)。
- 术后持续去甲肾上腺素给药时间中位数在de-escalation组为0.3小时 [0.0-5.5],剂量递增组为5.1小时 [0.0-14.3](P=0.003)。
- 术后症状性低血压发生率在de-escalation组为34.2%,剂量递增组为9.1%(P=0.005)。
- 住院时间中位数在de-escalation组为2.5天 [1.9-3.6],剂量递增组为7.1天 [6.0-11.9](P<0.001)。
- 两组并发症率无显著差异。
临床怎么用
- 在嗜铬细胞瘤肾上腺切除术中可考虑省略术前α阻滞剂剂量递增,以缩短住院时间,但需警惕术后症状性低血压。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study describes the effects of introducing a protocol omitting preoperative α-blockade dose-escalation (de-escalation) in a prospective patient group. BACKGROUND: The decline of mortality and morbidity associated with pheochromocytoma resection is frequently attributed to the introduction of preoperative α-blockade. Current protocols require preoperative α-blockade dose-escalation and multiple-day hospital admissions. However, correlating evidence is lacking. Moreover, recent data suggest equal perioperative safety regardless of preoperative α-blockade escalation. METHODS: Single-institution evaluation of protocol implementation, including patients who underwent adrenalectomy for pheochromocytoma between 2015 and 2023. Intraoperative hemodynamic control was regulated by active adjustment of blood pressure using vasoactive agents. The primary outcome was intraoperative hypertension, defined as the time-weighted average of systolic blood pressure (TWA-SBP) above 200 mm Hg. Secondary outcomes included perioperative hypotension, postoperative blood pressure support requirement, hospital stay duration, and complications. RESULTS: Of 102 pheochromocytoma patients, 82 were included; 44 in the de-escalated preoperative α-adrenergic protocol and 38 following the previous dose-escalation protocol. Median [IQR] TWA-SBP above 200 mm Hg was 0.01 [0.0-0.4] mm Hg in the de-escalated group versus 0.0 [0.0-0.1] mm Hg in the dose-escalated group ( P =0.073). The median duration of postoperative continuous norepinephrine administration was 0.3 hours [0.0-5.5] versus 5.1 hours [0.0-14.3], respectively ( P =0.003). Postoperative symptomatic hypotension occurred in 34.2% versus 9.1% of patients ( P =0.005). Median hospital stay was 2.5 days [1.9-3.6] versus 7.1 days [6.0-11.9] ( P <0.001). No significant differences in complication rates were observed. CONCLUSION: Our data suggest that adrenalectomy for pheochromocytoma employing a de-escalated preoperative α-blockade protocol is safe and results in a shorter hospital stay.
引用
- Holscher I, Engelsman AF, Dreijerink KMA, et al. Omitting the Escalating Dosage of Alpha-adrenergic Blockade Before Pheochromocytoma Resection: Implementation of a Treatment Strategy in Discordance With Current Guidelines. Ann Surg. 2024. PMID: 39105279. doi:10.1097/SLA.0000000000006493
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。